AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed

NoodlesOrTokens · 2026-03-27T13:21:35+00:00

AstraZeneca's stock rose 4% after its experimental lung disease drug, Tozorakimab, proved effective in late-stage trials for chronic obstructive pulmonary disease, marking a positive shift in market sentiment.

NoodlesOrTokens

2026-03-27 13:21:35

Abstract generation in progress

In this article

.FTSE
AZN-GB
ROG-CH

Follow your favorite stocksCREATE FREE ACCOUNT

AstraZeneca’s stock jumped as much as 4% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials.

The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease in both former smokers and in the overall population versus placebo, the company said.

“This marks a notable shift in sentiment, given limited conviction in the IL-33 mechanism following prior IL-33 failures from Sanofi and Roche,” said Jefferies analysts.

Tozorakimab and rival drugs belong to a class of treatments called monoclonal antibodies. They work by suppressing the action ⁠of the protein interleukin-33 (IL-33) and can reduce inflammation.

London-listed shares were last seen up 3.5% in midday trading, contrasting with the UK’s FTSE 100 index which fell 0.6%.

This is a breaking news story. Please refresh for updates.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.